High-dose itraconazole as a noncastrating therapy for a patient with biochemically recurrent prostate cancer

Daniel L. Suzman, Emmanuel S. Antonarakis

Research output: Contribution to journalArticle

Abstract

The role of androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer is unclear and is associated with significant adverse events. Itraconazole has demonstrated clinical activity in castration-resistant prostate cancer (CRPC) and does not appear to mediate its activity by androgen suppression. In this patient with biochemically recurrent prostate cancer, off-label treatment with itraconazole 600 mg/d resulted in a > 50% decline in prostatespecific antigen (PSA) levels, without evidence of testosterone suppression. Inhibition of the Hedgehog (Hh) pathway may mediate the clinical activity of itraconazole. Clinical trials are ongoing to further elucidate this mechanism in men ith biochemically recurrent and castration-resistant prostate cancer.

Original languageEnglish (US)
Pages (from-to)e51-e53
JournalClinical Genitourinary Cancer
Volume12
Issue number2
DOIs
StatePublished - Apr 2014

Keywords

  • Biochemical recurrence
  • Hedgehog pathway
  • Itraconazole
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint Dive into the research topics of 'High-dose itraconazole as a noncastrating therapy for a patient with biochemically recurrent prostate cancer'. Together they form a unique fingerprint.

  • Cite this